Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Acer Therapeutics stock | $2.96

Own Acer Therapeutics stock in just a few minutes.

Fact checked

Acer Therapeutics Inc is a biotechnology business based in the US. Acer Therapeutics shares (ACER) are listed on the NASDAQ and all prices are listed in US Dollars. Acer Therapeutics employs 20 staff and has a market cap (total outstanding shares value) of USD$32.6 million.

How to buy shares in Acer Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Acer Therapeutics. Find the stock by name or ticker symbol: ACER. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Acer Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.96, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Acer Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Acer Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Acer Therapeutics share price

Use our graph to track the performance of ACER stocks over time.

Acer Therapeutics shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$2.96
52-week rangeUSD$1.08 - USD$6.1
50-day moving average USD$2.6176
200-day moving average USD$3.0153
Wall St. target priceUSD$10
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.195

Buy Acer Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Acer Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Acer Therapeutics price performance over time

Historical closes compared with the close of $2.96 from 2020-10-19

1 week (2021-01-15) -23.12%
1 month (2020-12-23) 12.98%
3 months (2020-10-23) 6.47%
6 months (2020-07-23) -9.48%
1 year (2020-01-23) -33.63%
2 years (2019-01-23) -88.16%
3 years (2018-01-23) 18.8
5 years (2016-01-22) 53.98%

Acer Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -66.68%
Return on equity TTM -130.69%
Profit margin 0%
Book value $0.882
Market capitalisation USD$32.6 million

TTM: trailing 12 months

Shorting Acer Therapeutics shares

There are currently 497,644 Acer Therapeutics shares held short by investors – that's known as Acer Therapeutics's "short interest". This figure is 43% up from 347,970 last month.

There are a few different ways that this level of interest in shorting Acer Therapeutics shares can be evaluated.

Acer Therapeutics's "short interest ratio" (SIR)

Acer Therapeutics's "short interest ratio" (SIR) is the quantity of Acer Therapeutics shares currently shorted divided by the average quantity of Acer Therapeutics shares traded daily (recently around 114400.91954023). Acer Therapeutics's SIR currently stands at 4.35. In other words for every 100,000 Acer Therapeutics shares traded daily on the market, roughly 4350 shares are currently held short.

However Acer Therapeutics's short interest can also be evaluated against the total number of Acer Therapeutics shares, or, against the total number of tradable Acer Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acer Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Acer Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0556% of the tradable shares (for every 100,000 tradable Acer Therapeutics shares, roughly 56 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acer Therapeutics.

Find out more about how you can short Acer Therapeutics stock.

Acer Therapeutics share dividends

We're not expecting Acer Therapeutics to pay a dividend over the next 12 months.

Have Acer Therapeutics's shares ever split?

Acer Therapeutics's shares were split on a 96:1000 basis on 21 September 2017. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 96 shares. This wouldn't directly have changed the overall worth of your Acer Therapeutics shares – just the quantity. However, indirectly, the new 941.7% higher share price could have impacted the market appetite for Acer Therapeutics shares which in turn could have impacted Acer Therapeutics's share price.

Acer Therapeutics share price volatility

Over the last 12 months, Acer Therapeutics's shares have ranged in value from as little as $1.08 up to $6.1. A popular way to gauge a stock's volatility is its "beta".

ACER.US volatility(beta: 1.36)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acer Therapeutics's is 1.3626. This would suggest that Acer Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Acer Therapeutics overview

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of induced Vasomotor Symptoms. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site